Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
6.32
+0.10 (1.61%)
At close: Oct 5, 2026, 4:00 PM EDT
6.41
+0.09 (1.42%)
After-hours: Oct 5, 2026, 5:41 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 149 employees as of June 30, 2026. The number of employees increased by 20 or 15.50% compared to the same quarter last year.
Employees
149
Change
20
Growth
15.50%
Revenue / Employee
n/a
Profits / Employee
-$1,024,416
Market Cap
390.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 149 | 20 | 15.50% |
| Mar 31, 2026 | 129 | 10 | 8.40% |
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Sep 30, 2025 | 129 | 10 | 8.40% |
| Jun 30, 2025 | 129 | 17 | 15.18% |
| Mar 31, 2025 | 119 | 19 | 19.00% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Sep 30, 2024 | 119 | 30 | 33.71% |
| Jun 30, 2024 | 112 | 23 | 25.84% |
| Mar 31, 2024 | 100 | - | - |
| Dec 31, 2023 | 96 | - | - |
| Sep 30, 2023 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enanta Pharmaceuticals | 120 |
| Arcturus Therapeutics Holdings | 111 |
| Agenus | 81 |
| Prelude Therapeutics | 79 |
| Zura Bio | 40 |
| Opus Genetics | 28 |
| vTv Therapeutics | 26 |
| Relmada Therapeutics | 17 |
KYTX News
- 11 days ago - Kyverna Therapeutics Transcript: Study update - Transcripts
- 11 days ago - Kyverna Therapeutics Press release: Study update - Filings
- 11 days ago - Kyverna Therapeutics Slides: Study update - Filings
- 11 days ago - Kyverna Therapeutics Slides: Investor presentation - Filings
- 11 days ago - Swarmer’s miv-cel shows positive results in stiff person syndrome and gMG - TheFly
- 11 days ago - Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis - GlobeNewsWire
- 20 days ago - Kyverna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 21 days ago - Kyverna Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts